Delaney Herper
Physician Assistant · Tampa, FLNPI 1235736794
Payments from drug & device makers
Across 115 payments — averaging $26.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$493
- Johnson & Johnson$466
- AbbVie$465
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$358
- Alkermes, Inc.$274
- Takeda Pharmaceuticals U.S.A., Inc.$193
- plus $816 from 15 others
What the payments were for
- Food & beverage$3,066100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $493 |
| Johnson & Johnson | 10 | $466 |
| AbbVie | 29 | $465 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $358 |
| Alkermes, Inc. | 10 | $274 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $193 |
| Teva Pharmaceuticals USA, Inc. | 5 | $187 |
| Neurocrine Biosciences, Inc. | 4 | $170 |
| Almatica Pharma LLC | 3 | $68 |
| Corium, LLC | 3 | $65 |
| Sunovion Pharmaceuticals Inc. | 4 | $49 |
| Eisai Inc. | 3 | $48 |
| Bausch Health US, LLC | 2 | $44 |
| Indivior Inc. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| Neos Therapeutics, LP | 1 | $20 |
| Tris Pharma Inc | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $16 |
| Merck | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$241
- SPRAVATO$222
- CAPLYTA$125
- INGREZZA$122
- AUSTEDO$122
- ABILIFY MAINTENA$122
- VRAYLAR$122
- INVEGA TRINZA$103
How this compares
$3,066 in reported general payments places this provider in the 80th percentile of 8,062 physician assistant providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $114,890 |
| Ziprasidone Hcl | 36 | $1,726 |
| Oxcarbazepine | 14 | $1,019 |
| Bupropion XlBupropion Hcl | 16 | $797 |
| Duloxetine Hcl | 13 | $299 |
| Clonazepam | 11 | $170 |
| Lorazepam | 24 | $134 |
| Escitalopram Oxalate | 14 | $119 |
| Alprazolam | 17 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $170 | $114,89013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Tampa
- Kevin WilliamsTampa$647K
- Grace DoyleTampa$123K
- Kevin AllisonTampa$88K
- Tiffany ValoneTampa$62K
- David JohnsonTampa$51K
- Kimberly SidersTampa$47K
- Jaime ApplefieldTampa$39K
- Kenneth BoccaccioTampa$31K
- Mark HonorTampa$30K
- Richard MarshallPort Orange$988K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.